Respiratory viruses, such as influenza and SARS-CoV-2, pose a significant threat to global health. Despite advancements in vaccines and therapies, these viruses remain a major public health concern. A recent study investigated the potential of intranasal neomycin administration to induce antiviral protection in murine models. The findings revealed that intranasal neomycin evoked robust expression of interferon-stimulated genes (ISGs) in the upper respiratory tract, providing protection against both influenza A virus and SARS-CoV-2. This protection was independent of the host microbiome or interferon-related pathways. The study highlights the therapeutic and prophylactic potential of neomycin against respiratory viruses.